tizanidine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2683 51322-75-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • DS 103-282
  • tizanidine
  • tizanidine hydrochloride
  • tizanidine HCl
  • AN021
  • DS103-282
Tizanidine is an agonist at alpha2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.
  • Molecular weight: 253.71
  • Formula: C9H8ClN5S
  • CLOGP: 2.32
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 62.20
  • ALOGS: -3.28
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
12 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.36 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 21 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 27, 1996 FDA ACORDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 361.18 10.92 307 46498 42657 50515662
Pneumonia aspiration 223.30 10.92 203 46602 30801 50527518
Multiple sclerosis 187.77 10.92 154 46651 20339 50537980
Gastrooesophageal reflux disease 160.27 10.92 268 46537 76160 50482159
Somnolence 141.34 10.92 387 46418 154598 50403721
Coma 136.35 10.92 212 46593 56667 50501652
Completed suicide 136.20 10.92 345 46460 131544 50426775
Contraindicated product administered 107.18 10.92 8 46797 148950 50409369
Depression 104.09 10.92 363 46442 165060 50393259
Synovitis 97.28 10.92 4 46801 123861 50434458
Drug withdrawal syndrome 95.61 10.92 117 46688 24964 50533355
Migraine 87.28 10.92 206 46599 75074 50483245
Fall 85.03 10.92 565 46240 334367 50223952
Glossodynia 83.72 10.92 6 46799 115563 50442756
Maternal exposure during pregnancy 82.16 10.92 23 46782 159755 50398564
Muscle spasms 75.04 10.92 271 46534 125282 50433037
Systemic lupus erythematosus 69.09 10.92 22 46783 140600 50417719
Hypoaesthesia 68.00 10.92 265 46540 126992 50431327
Drug intolerance 67.43 10.92 62 46743 219042 50339277
Lower respiratory tract infection 63.40 10.92 7 46798 95194 50463125
Product dose omission issue 62.50 10.92 335 46470 183503 50374816
Neutropenia 61.45 10.92 30 46775 147935 50410384
Treatment failure 60.11 10.92 26 46779 137611 50420708
Infusion related reaction 59.63 10.92 42 46763 169515 50388804
Suspected suicide 59.26 10.92 45 46760 5312 50553007
Pericarditis 57.23 10.92 4 46801 78685 50479634
Urinary tract infection 56.17 10.92 377 46428 223643 50334676
Exposure during pregnancy 55.88 10.92 21 46784 120994 50437325
Withdrawal syndrome 54.40 10.92 74 46731 17516 50540803
Gait disturbance 54.16 10.92 278 46527 149727 50408592
Joint swelling 45.12 10.92 100 46705 245186 50313133
Stiff person syndrome 44.77 10.92 14 46791 217 50558102
Autonomic dysreflexia 43.69 10.92 15 46790 316 50558003
Neck pain 42.77 10.92 133 46672 56934 50501385
Thrombocytopenia 41.83 10.92 34 46771 127639 50430680
General physical health deterioration 39.57 10.92 44 46761 142390 50415929
Anxiety 39.27 10.92 290 46515 177316 50381003
Febrile neutropenia 38.75 10.92 21 46784 97646 50460673
Muscle spasticity 38.31 10.92 62 46743 17122 50541197
Memory impairment 37.38 10.92 159 46646 79201 50479118
Wound 34.87 10.92 28 46777 105766 50452553
Helicobacter infection 34.80 10.92 3 46802 49699 50508620
Tremor 33.46 10.92 201 46604 114702 50443617
Drug ineffective 33.31 10.92 546 46259 818787 49739532
Headache 32.69 10.92 653 46152 505882 50052437
Pancytopenia 31.99 10.92 19 46786 84011 50474308
Muscular weakness 31.46 10.92 172 46633 94841 50463478
Back pain 31.28 10.92 326 46479 219704 50338615
Malignant neoplasm progression 31.14 10.92 12 46793 68112 50490207
Sleep apnoea syndrome 30.60 10.92 68 46737 23800 50534519
Influenza like illness 30.12 10.92 119 46686 57340 50500979
Feeling abnormal 30.09 10.92 209 46596 125283 50433036
Dysphoria 30.01 10.92 29 46776 4745 50553574
Paraesthesia 29.26 10.92 201 46604 120042 50438277
Alopecia 29.20 10.92 122 46683 244925 50313394
Intervertebral disc protrusion 28.31 10.92 60 46745 20333 50537986
Insomnia 28.20 10.92 266 46539 174599 50383720
Off label use 28.10 10.92 292 46513 474134 50084185
Therapeutic product effect decreased 27.94 10.92 52 46753 135998 50422321
Rash 27.68 10.92 265 46540 437206 50121113
Hypersensitivity 26.33 10.92 106 46699 215055 50343264
Folliculitis 25.81 10.92 3 46802 39222 50519097
Vision blurred 25.11 10.92 141 46664 78506 50479813
Amnesia 25.02 10.92 91 46714 42169 50516150
Pain 23.60 10.92 701 46104 578202 49980117
Therapy interrupted 23.17 10.92 55 46750 20097 50538222
Neurogenic bladder 23.13 10.92 20 46785 2837 50555482
Cardiac failure 22.79 10.92 22 46783 76018 50482301
Vitamin D deficiency 22.56 10.92 39 46766 11363 50546956
Arthropathy 22.48 10.92 73 46732 157833 50400486
Lumbar radiculopathy 22.31 10.92 16 46789 1730 50556589
Visual impairment 22.19 10.92 123 46682 68152 50490167
Suspected product quality issue 22.13 10.92 8 46797 197 50558122
Muscle injury 21.74 10.92 4 46801 37107 50521212
Hallucination 21.59 10.92 93 46712 46564 50511755
Hepatic enzyme increased 21.35 10.92 61 46744 137319 50421000
JC polyomavirus test positive 21.04 10.92 13 46792 1096 50557223
Suicidal ideation 20.90 10.92 104 46701 55281 50503038
Blood pressure systolic increased 20.38 10.92 4 46801 35445 50522874
Balance disorder 20.23 10.92 123 46682 70467 50487852
COVID-19 20.07 10.92 91 46714 46571 50511748
Sleep disorder due to general medical condition, insomnia type 19.28 10.92 3 46802 31444 50526875
Swelling 19.27 10.92 108 46697 200764 50357555
Pre-existing condition improved 19.19 10.92 28 46777 7069 50551250
C-reactive protein increased 19.04 10.92 20 46785 66454 50491865
Formication 18.98 10.92 20 46785 3626 50554693
Therapeutic response unexpected 18.91 10.92 44 46761 15871 50542448
Therapy cessation 18.91 10.92 60 46745 25951 50532368
Spinal operation 18.85 10.92 26 46779 6234 50552085
Back disorder 18.64 10.92 32 46773 9273 50549046
Drug dependence 18.61 10.92 50 46755 19709 50538610
Rheumatoid arthritis 18.31 10.92 111 46694 202439 50355880
Respiratory arrest 18.08 10.92 65 46740 29944 50528375
Product use issue 18.04 10.92 74 46731 149401 50408918
International normalised ratio increased 17.52 10.92 9 46796 43143 50515176
Progressive multiple sclerosis 17.32 10.92 10 46795 745 50557574
Intentional product misuse 17.10 10.92 87 46718 46647 50511672
Surgery 17.00 10.92 64 46741 30141 50528178
Nervousness 16.75 10.92 60 46745 27591 50530728
Decreased interest 16.71 10.92 17 46788 2959 50555360
Acute kidney injury 16.66 10.92 133 46672 227925 50330394
Blood creatinine increased 16.63 10.92 28 46777 76132 50482187
Abdominal discomfort 16.50 10.92 136 46669 231505 50326814
Neuralgia 16.41 10.92 51 46754 21812 50536507
Peroneal nerve palsy 16.35 10.92 20 46785 4263 50554056
Anaemia 16.32 10.92 152 46653 252304 50306015
Urinary incontinence 16.07 10.92 60 46745 28148 50530171
Central nervous system lesion 15.66 10.92 30 46775 9459 50548860
Dysarthria 15.38 10.92 72 46733 37331 50520988
Disease progression 15.31 10.92 42 46763 95824 50462495
Respiratory alkalosis 15.27 10.92 15 46790 2504 50555815
Fibromyalgia 15.26 10.92 82 46723 44896 50513423
Temperature intolerance 15.20 10.92 26 46779 7513 50550806
Loss of consciousness 14.98 10.92 155 46650 104198 50454121
Secondary progressive multiple sclerosis 14.81 10.92 11 46794 1255 50557064
Intervertebral disc degeneration 14.68 10.92 36 46769 13425 50544894
Dizziness 14.48 10.92 421 46384 345948 50212371
Haemorrhagic diathesis 14.37 10.92 18 46787 3930 50554389
Cholestasis 14.32 10.92 3 46802 25398 50532921
Cardio-respiratory arrest 14.25 10.92 92 46713 53800 50504519
Neutrophil count decreased 14.16 10.92 13 46792 46013 50512306
Bone marrow failure 14.14 10.92 4 46801 27620 50530699
Impaired healing 14.03 10.92 27 46778 69759 50488560
Ankle fracture 14.02 10.92 39 46766 15683 50542636
Mucosal inflammation 14.02 10.92 10 46795 40132 50518187
Hyperhidrosis 13.88 10.92 135 46670 89291 50469028
Pneumonitis 13.81 10.92 5 46800 29505 50528814
Mental status changes 13.61 10.92 68 46737 36204 50522115
Appetite disorder 13.55 10.92 22 46783 6092 50552227
Pyrexia 13.54 10.92 259 46546 379944 50178375
Device expulsion 13.29 10.92 5 46800 28817 50529502
Hyperkalaemia 13.18 10.92 15 46790 48074 50510245
Thinking abnormal 13.11 10.92 28 46777 9539 50548780
Fibula fracture 13.04 10.92 15 46790 2997 50555322
Illness 13.00 10.92 51 46754 24489 50533830
Nasopharyngitis 12.96 10.92 115 46690 192812 50365507
Optic neuritis 12.90 10.92 23 46782 6867 50551452
Hepatocellular injury 12.84 10.92 4 46801 25943 50532376
Nerve compression 12.82 10.92 24 46781 7438 50550881
Spinal fusion acquired 12.77 10.92 3 46802 14 50558305
Hypertonia 12.72 10.92 17 46788 3956 50554363
Relapsing-remitting multiple sclerosis 12.66 10.92 7 46798 480 50557839
Panic attack 12.61 10.92 43 46762 19299 50539020
Cervical spinal stenosis 12.58 10.92 12 46793 1931 50556388
Impaired gastric emptying 12.51 10.92 26 46779 8692 50549627
Multiple organ dysfunction syndrome 12.44 10.92 17 46788 50320 50507999
Ascites 12.44 10.92 9 46796 35852 50522467
Loss of control of legs 12.38 10.92 10 46795 1291 50557028
Normocytic anaemia 12.21 10.92 10 46795 1317 50557002
Head injury 11.98 10.92 49 46756 23971 50534348
Blood pressure orthostatic 11.84 10.92 4 46801 80 50558239
Gastrointestinal haemorrhage 11.80 10.92 32 46773 73289 50485030
Muscle tightness 11.75 10.92 28 46777 10252 50548067
Spinal osteoarthritis 11.64 10.92 34 46771 14058 50544261
Road traffic accident 11.62 10.92 49 46756 24303 50534016
Urosepsis 11.54 10.92 36 46769 15429 50542890
Underdose 11.44 10.92 43 46762 20235 50538084
Drug dependence, antepartum 11.28 10.92 3 46802 25 50558294
Gastrointestinal disorder 11.24 10.92 47 46758 94409 50463910
Seizure 11.21 10.92 162 46643 117712 50440607
Back injury 11.20 10.92 22 46783 7063 50551256
Acute febrile neutrophilic dermatosis 11.17 10.92 13 46792 2629 50555690
Loss of bladder sensation 11.08 10.92 3 46802 27 50558292
Bronchitis 11.06 10.92 146 46659 104013 50454306
Tremor neonatal 11.05 10.92 4 46801 99 50558220
Diplopia 11.00 10.92 41 46764 19219 50539100

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 113.95 13.42 69 13567 11350 29549541
Multiple sclerosis 110.24 13.42 53 13583 5501 29555390
Completed suicide 96.27 13.42 159 13477 90087 29470804
Drug withdrawal syndrome 73.16 13.42 63 13573 17921 29542970
Potassium wasting nephropathy 65.39 13.42 14 13622 91 29560800
Muscle spasticity 57.89 13.42 33 13603 4850 29556041
Failure to suspend medication 55.92 13.42 16 13620 376 29560515
Depression 46.99 13.42 114 13522 85033 29475858
Muscle spasms 46.98 13.42 97 13539 64985 29495906
Back pain 43.25 13.42 124 13512 102160 29458731
Intervertebral disc protrusion 38.59 13.42 32 13604 8638 29552253
Febrile neutropenia 35.15 13.42 5 13631 112235 29448656
Pain 35.01 13.42 164 13472 171268 29389623
Urinary tract infection 33.80 13.42 91 13545 72263 29488628
Suspected suicide 31.84 13.42 21 13615 3999 29556892
Accidental death 29.73 13.42 16 13620 2102 29558789
Wrong patient received product 28.61 13.42 16 13620 2266 29558625
Anxiety 28.18 13.42 95 13541 85270 29475621
Drug dependence 27.92 13.42 41 13595 20940 29539951
Fall 27.47 13.42 157 13479 177021 29383870
Progressive multiple sclerosis 26.56 13.42 8 13628 226 29560665
Anaemia 25.72 13.42 33 13603 200918 29359973
Gait disturbance 25.43 13.42 83 13553 73266 29487625
Hypoaesthesia 24.71 13.42 67 13569 53400 29507491
Inadequate analgesia 23.82 13.42 15 13621 2639 29558252
Motor dysfunction 22.54 13.42 20 13616 5910 29554981
Memory impairment 22.45 13.42 51 13585 36419 29524472
Neuralgia 21.82 13.42 26 13610 10848 29550043
Drug abuser 21.05 13.42 16 13620 3811 29557080
Neutropenia 20.91 13.42 18 13618 131693 29429198
Spinal cord injury cauda equina 20.77 13.42 6 13630 146 29560745
Somatosensory evoked potentials abnormal 20.54 13.42 6 13630 152 29560739
General physical health deterioration 20.40 13.42 11 13625 102846 29458045
Autonomic dysreflexia 19.97 13.42 5 13631 69 29560822
Vitamin B6 deficiency 19.74 13.42 6 13630 175 29560716
Thrombocytopenia 19.55 13.42 20 13616 134803 29426088
Dysdiadochokinesis 19.21 13.42 6 13630 192 29560699
Urobilinogen urine increased 19.14 13.42 7 13629 365 29560526
Drug tolerance 18.90 13.42 12 13624 2141 29558750
Road traffic accident 18.70 13.42 29 13607 15532 29545359
Movement disorder 18.16 13.42 23 13613 10214 29550677
Kidney enlargement 17.93 13.42 8 13628 699 29560192
Unemployment 17.85 13.42 4 13632 33 29560858
Pancytopenia 17.84 13.42 8 13628 83160 29477731
Blood folate increased 17.65 13.42 6 13630 252 29560639
Sedation 17.60 13.42 30 13606 17375 29543516
Insomnia 17.40 13.42 84 13552 88677 29472214
Urine uric acid decreased 17.37 13.42 5 13631 120 29560771
Urinary sediment abnormal 17.22 13.42 5 13631 124 29560767
Pain in extremity 17.17 13.42 98 13538 110335 29450556
Respiratory arrest 16.87 13.42 37 13599 25796 29535095
Burning sensation 16.82 13.42 28 13608 15910 29544981
Lipomatosis 16.38 13.42 6 13630 314 29560577
Fear of falling 16.10 13.42 6 13630 330 29560561
Secondary progressive multiple sclerosis 15.63 13.42 6 13630 358 29560533
Muscle strength abnormal 15.61 13.42 4 13632 61 29560830
Decreased vibratory sense 15.50 13.42 6 13630 366 29560525
Respiratory paralysis 15.49 13.42 4 13632 63 29560828
Implant site infection 15.40 13.42 8 13628 978 29559913
Musculoskeletal stiffness 15.39 13.42 45 13591 37413 29523478
Gait inability 15.17 13.42 29 13607 18346 29542545
Mobility decreased 14.70 13.42 35 13601 25745 29535146
Headache 14.56 13.42 133 13503 173874 29387017
Fine motor skill dysfunction 14.51 13.42 9 13627 1542 29559349
Malignant neoplasm progression 14.49 13.42 8 13628 73851 29487040
Osteochondrosis 13.92 13.42 7 13629 800 29560091
Cardio-respiratory arrest 13.85 13.42 53 13583 50548 29510343
Muscular weakness 13.83 13.42 61 13575 61991 29498900
Hyponatraemia 13.75 13.42 7 13629 67626 29493265
Back injury 13.74 13.42 12 13624 3472 29557419
Spinal fusion surgery 13.58 13.42 7 13629 842 29560049

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 369.40 11.09 278 47179 40857 64410418
Multiple sclerosis 254.49 11.09 164 47293 18777 64432498
Completed suicide 227.00 11.09 506 46951 223908 64227367
Drug withdrawal syndrome 156.19 11.09 151 47306 31140 64420135
Pneumonia aspiration 153.07 11.09 203 47254 59068 64392207
Gastrooesophageal reflux disease 140.08 11.09 233 47224 82910 64368365
Somnolence 118.47 11.09 374 47083 203271 64248004
Depression 104.18 11.09 334 47123 182957 64268318
Urinary tract infection 99.69 11.09 385 47072 231211 64220064
Coma 99.16 11.09 207 47250 87408 64363867
Migraine 96.76 11.09 169 47288 62508 64388767
Muscle spasms 93.22 11.09 271 47186 140752 64310523
Fall 89.46 11.09 568 46889 416258 64035017
Hypoaesthesia 81.29 11.09 256 47201 138852 64312423
Suspected suicide 78.75 11.09 59 47398 8595 64442680
Neutropenia 77.17 11.09 40 47417 239584 64211691
Febrile neutropenia 72.22 11.09 24 47433 187633 64263642
Muscle spasticity 71.31 11.09 74 47383 16595 64434680
Gait disturbance 67.43 11.09 278 47179 171877 64279398
Pain 63.68 11.09 654 46803 552857 63898418
Autonomic dysreflexia 59.88 11.09 19 47438 394 64450881
Intervertebral disc protrusion 58.11 11.09 73 47384 20118 64431157
Thrombocytopenia 56.42 11.09 49 47408 223752 64227523
General physical health deterioration 56.25 11.09 41 47416 204384 64246891
Back pain 54.82 11.09 343 47114 249828 64201447
Potassium wasting nephropathy 52.68 11.09 14 47443 150 64451125
Neck pain 50.38 11.09 128 47329 61405 64389870
Withdrawal syndrome 49.48 11.09 73 47384 23419 64427856
Pancytopenia 49.04 11.09 22 47435 143287 64307988
Lower respiratory tract infection 46.58 11.09 7 47450 94607 64356668
Stiff person syndrome 46.19 11.09 14 47443 248 64451027
Failure to suspend medication 44.08 11.09 15 47442 390 64450885
Headache 44.06 11.09 588 46869 528879 63922396
Product dose omission issue 43.25 11.09 268 47189 194479 64256796
Off label use 42.56 11.09 282 47175 632524 63818751
Acute kidney injury 42.00 11.09 179 47278 449061 64002214
Contraindicated product administered 39.40 11.09 15 47442 107814 64343461
Malignant neoplasm progression 39.13 11.09 17 47440 112854 64338421
Memory impairment 38.89 11.09 145 47312 85537 64365738
Insomnia 37.10 11.09 261 47196 197575 64253700
Infusion related reaction 35.70 11.09 41 47416 164426 64286849
Feeling abnormal 34.93 11.09 192 47265 133410 64317865
Anxiety 34.93 11.09 262 47195 202387 64248888
Pericarditis 34.83 11.09 3 47454 62513 64388762
Cardiac failure 34.54 11.09 28 47429 132345 64318930
Drug dependence 34.54 11.09 76 47381 33236 64418039
Maternal exposure during pregnancy 33.94 11.09 14 47443 95870 64355405
Anaemia 33.48 11.09 154 47303 378526 64072749
Lumbar radiculopathy 33.36 11.09 19 47438 1738 64449537
Glossodynia 31.35 11.09 5 47452 64691 64386584
Influenza like illness 31.04 11.09 108 47349 61594 64389681
Progressive multiple sclerosis 31.02 11.09 14 47443 782 64450493
Visual impairment 30.05 11.09 121 47336 73956 64377319
Muscular weakness 30.00 11.09 178 47279 127160 64324115
Drug intolerance 29.98 11.09 58 47399 187934 64263341
Treatment failure 28.90 11.09 26 47431 116790 64334485
Blood creatinine increased 27.20 11.09 36 47421 135746 64315529
Neurogenic bladder 27.12 11.09 22 47435 3597 64447678
Respiratory arrest 26.01 11.09 92 47365 52893 64398382
Road traffic accident 24.17 11.09 63 47394 30682 64420593
Cardio-respiratory arrest 24.12 11.09 139 47318 98254 64353021
Mucosal inflammation 24.06 11.09 8 47449 62576 64388699
Platelet count decreased 24.00 11.09 55 47402 167656 64283619
Dysphoria 23.45 11.09 22 47435 4366 64446909
Drug abuser 23.44 11.09 25 47432 5783 64445492
Urinary incontinence 23.39 11.09 69 47388 36082 64415193
Hyperkalaemia 23.28 11.09 24 47433 101105 64350170
Hypersensitivity 23.13 11.09 71 47386 196381 64254894
JC polyomavirus test positive 22.24 11.09 13 47444 1249 64450026
Neuralgia 21.98 11.09 55 47402 26129 64425146
Inadequate analgesia 21.37 11.09 20 47437 3958 64447317
Mental status changes 21.01 11.09 95 47362 61067 64390208
Tremor 20.83 11.09 183 47274 148047 64303228
Exposure during pregnancy 20.80 11.09 16 47441 77659 64373616
Bone marrow failure 20.52 11.09 5 47452 47947 64403328
International normalised ratio increased 20.33 11.09 17 47440 79150 64372125
Dizziness 20.31 11.09 436 47021 429727 64021548
Multiple organ dysfunction syndrome 20.20 11.09 27 47430 101386 64349889
Joint swelling 19.96 11.09 86 47371 215296 64235979
Paraesthesia 19.91 11.09 168 47289 134354 64316921
Peroneal nerve palsy 19.90 11.09 22 47435 5299 64445976
Vision blurred 19.84 11.09 124 47333 90192 64361083
Secondary progressive multiple sclerosis 19.81 11.09 12 47445 1231 64450044
Systemic lupus erythematosus 19.52 11.09 17 47440 77595 64373680
Gait inability 19.46 11.09 72 47385 42296 64408979
Back injury 19.14 11.09 26 47431 7731 64443544
Hallucination 18.60 11.09 104 47353 72684 64378591
Muscle tightness 18.49 11.09 31 47426 11084 64440191
Gastrointestinal haemorrhage 18.44 11.09 44 47413 132268 64319007
Disease progression 18.29 11.09 49 47408 141631 64309644
Urinary sediment abnormal 18.29 11.09 6 47451 139 64451136
Back disorder 18.16 11.09 29 47428 9961 64441314
Amnesia 18.12 11.09 77 47380 48192 64403083
Dysarthria 18.02 11.09 89 47368 59317 64391958
Spinal cord injury cauda equina 18.01 11.09 6 47451 146 64451129
Pyrexia 18.00 11.09 296 47161 558348 63892927
Toxic epidermal necrolysis 17.72 11.09 3 47454 37163 64414112
Ascites 17.61 11.09 12 47445 61989 64389286
Panic attack 17.57 11.09 44 47413 20909 64430366
Spinal osteoarthritis 17.53 11.09 35 47422 14306 64436969
Vitamin D deficiency 17.35 11.09 31 47426 11661 64439614
Drug hypersensitivity 17.23 11.09 258 47199 237557 64213718
Intervertebral disc degeneration 17.22 11.09 33 47424 13087 64438188
Hyponatraemia 17.18 11.09 54 47403 148285 64302990
Balance disorder 17.06 11.09 113 47344 83813 64367462
Hepatocellular injury 17.01 11.09 6 47451 45229 64406046
Somatosensory evoked potentials abnormal 16.79 11.09 6 47451 181 64451094
Accidental death 16.77 11.09 17 47440 3708 64447567
Surgery 16.52 11.09 52 47405 28161 64423114
Renal impairment 16.46 11.09 48 47409 134969 64316306
Thinking abnormal 16.33 11.09 30 47427 11526 64439749
Formication 16.27 11.09 18 47439 4339 64446936
Atrial fibrillation 16.04 11.09 68 47389 171021 64280254
Neutrophil count decreased 15.94 11.09 20 47437 77176 64374099
Pain in extremity 15.86 11.09 312 47145 302773 64148502
Melaena 15.70 11.09 10 47447 53538 64397737
Therapy interrupted 15.69 11.09 41 47416 19995 64431280
Cytomegalovirus infection 15.68 11.09 4 47453 37195 64414080
Therapy cessation 15.59 11.09 56 47401 32433 64418842
Burning sensation 15.49 11.09 75 47382 49589 64401686
C-reactive protein increased 15.37 11.09 29 47428 94880 64356395
Urobilinogen urine increased 15.23 11.09 8 47449 624 64450651
Movement disorder 15.21 11.09 43 47414 21957 64429318
Urine uric acid decreased 15.07 11.09 5 47452 120 64451155
Angioedema 15 11.09 14 47443 61807 64389468
Renal failure 14.80 11.09 76 47381 181612 64269663
Bladder disorder 14.74 11.09 23 47434 7744 64443531
Unemployment 14.64 11.09 4 47453 48 64451227
Spinal operation 14.29 11.09 20 47437 6113 64445162
Vitamin B6 deficiency 14.21 11.09 6 47451 285 64450990
Motor dysfunction 14.19 11.09 28 47429 11345 64439930
Loss of control of legs 14.17 11.09 11 47446 1688 64449587
Productive cough 14.06 11.09 20 47437 73183 64378092
Nerve compression 14.03 11.09 22 47435 7439 64443836
Paraparesis 14.00 11.09 15 47442 3487 64447788
Bedridden 13.98 11.09 26 47431 10083 64441192
Leukopenia 13.84 11.09 34 47423 101208 64350067
Arterial perforation 13.83 11.09 3 47454 12 64451263
Fibula fracture 13.73 11.09 14 47443 3074 64448201
Dysdiadochokinesis 13.72 11.09 6 47451 311 64450964
Respiratory paralysis 13.63 11.09 4 47453 63 64451212
Circulatory collapse 13.52 11.09 4 47453 33728 64417547
Appetite disorder 13.49 11.09 20 47437 6441 64444834
Interstitial lung disease 13.22 11.09 33 47424 97699 64353576
Product quality issue 13.15 11.09 50 47407 29749 64421526
Wrong patient received product 13.12 11.09 15 47442 3747 64447528
Concussion 13.02 11.09 22 47435 7916 64443359
Haemoglobin decreased 13.01 11.09 87 47370 194976 64256299
Asthenia 12.92 11.09 409 47048 427635 64023640
Haemorrhagic diathesis 12.88 11.09 18 47439 5496 64445779
pH urine decreased 12.82 11.09 3 47454 18 64451257
Head injury 12.80 11.09 53 47404 32789 64418486
Intentional product misuse 12.73 11.09 94 47363 72201 64379074
Pneumonitis 12.70 11.09 11 47446 50354 64400921
Fibromyalgia 12.64 11.09 56 47401 35675 64415600
Epistaxis 12.61 11.09 34 47423 98097 64353178
Lipomatosis 12.54 11.09 6 47451 383 64450892
Septic shock 12.47 11.09 38 47419 105399 64345876
Ankle fracture 12.45 11.09 31 47426 14679 64436596
Hepatotoxicity 12.36 11.09 7 47450 39955 64411320
Device allergy 12.30 11.09 3 47454 22 64451253
Osteonecrosis of jaw 12.29 11.09 7 47450 39818 64411457
Nerve injury 12.21 11.09 21 47436 7664 64443611
Implant site infection 12.20 11.09 10 47447 1659 64449616
Lymphocyte percentage decreased 12.11 11.09 16 47441 4633 64446642
Implant site swelling 12.07 11.09 6 47451 417 64450858
Stress 12.00 11.09 81 47376 60453 64390822
CSF immunoglobulin increased 11.96 11.09 3 47454 25 64451250
Drug dependence, antepartum 11.96 11.09 3 47454 25 64451250
Hepatic enzyme increased 11.96 11.09 52 47405 129891 64321384
Tibia fracture 11.85 11.09 16 47441 4729 64446546
Spinal fusion surgery 11.80 11.09 14 47443 3637 64447638
Tubulointerstitial nephritis 11.79 11.09 4 47453 30905 64420370
Nervousness 11.76 11.09 48 47409 29508 64421767
White blood cells urine positive 11.69 11.09 17 47440 5381 64445894
Loss of consciousness 11.54 11.09 163 47294 148202 64303073
Medical device site pain 11.51 11.09 5 47452 255 64451020
Acute myeloid leukaemia 11.49 11.09 3 47454 27460 64423815
Neurotoxicity 11.45 11.09 3 47454 27401 64423874
Kidney enlargement 11.43 11.09 8 47449 1048 64450227
Agranulocytosis 11.40 11.09 7 47450 38222 64413053
Injection site bruising 11.39 11.09 55 47402 36318 64414957
Impaired gastric emptying 11.38 11.09 22 47435 8782 64442493
Muscle strength abnormal 11.38 11.09 4 47453 115 64451160
Mucosa vesicle 11.30 11.09 3 47454 32 64451243
Blood folate increased 11.29 11.09 6 47451 479 64450796
T-lymphocyte count decreased 11.27 11.09 6 47451 481 64450794
Bronchitis 11.25 11.09 126 47331 108617 64342658
Acute febrile neutrophilic dermatosis 11.15 11.09 13 47444 3316 64447959
Temperature intolerance 11.13 11.09 21 47436 8234 64443041
Intervertebral disc disorder 11.09 11.09 15 47442 4442 64446833

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M03BX02 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Other centrally acting agents
FDA MoA N0000009918 Adrenergic alpha2-Agonists
FDA EPC N0000175554 Central alpha-2 Adrenergic Agonist
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000700 Analgesics
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35569 alpha-adrenergic agonists
CHEBI has role CHEBI:51371 muscle relaxants

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Spasticity indication 221360009
Muscle spasticity of spinal origin indication 416830008
Muscle Spasticity of Cerebral Origin indication
Low blood pressure contraindication 45007003
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Psychotic disorder contraindication 69322001
Kidney disease contraindication 90708001 DOID:557




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR AGONIST EC50 7.07 CHEMBL CHEMBL
Alpha-2B adrenergic receptor GPCR AGONIST WOMBAT-PK CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST EC50 5.91 CHEMBL CHEMBL
Nischarin Membrane receptor Ki 7.55 CHEMBL
Alpha-1A adrenergic receptor GPCR EC50 6.58 CHEMBL
Alpha-1B adrenergic receptor GPCR EC50 6.49 CHEMBL

External reference:

IDSource
4021025 VUID
N0000148492 NUI
D00776 KEGG_DRUG
64461-82-1 SECONDARY_CAS_RN
4021025 VANDF
4021027 VANDF
C0146011 UMLSCUI
CHEBI:63629 CHEBI
CHEMBL1079 ChEMBL_ID
CHEMBL1200329 ChEMBL_ID
DB00697 DRUGBANK_ID
C023754 MESH_SUPPLEMENTAL_RECORD_UI
5487 PUBCHEM_CID
7308 IUPHAR_LIGAND_ID
4697 INN_ID
6AI06C00GW UNII
236460 RXNORM
22951 MMSL
44068 MMSL
5589 MMSL
d04102 MMSL
006021 NDDF
006022 NDDF
108461005 SNOMEDCT_US
108462003 SNOMEDCT_US
373440006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
tizanidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0034 TABLET 2 mg ORAL ANDA 27 sections
tizanidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-4400 TABLET 4 mg ORAL ANDA 27 sections
tizanidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2788 CAPSULE, GELATIN COATED 2 mg ORAL NDA 26 sections
tizanidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2789 CAPSULE, GELATIN COATED 4 mg ORAL NDA 26 sections
tizanidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2790 CAPSULE, GELATIN COATED 6 mg ORAL NDA 26 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 0615-5574 TABLET 4 mg ORAL ANDA 25 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 0615-6564 TABLET 2 mg ORAL ANDA 25 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 0615-8274 TABLET 4 mg ORAL ANDA 27 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 0615-8360 TABLET 2 mg ORAL ANDA 27 sections
tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6418 TABLET 4 mg ORAL ANDA 18 sections
tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6418 TABLET 4 mg ORAL ANDA 18 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6898 TABLET 4 mg ORAL ANDA 27 sections
tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 10544-576 TABLET 4 mg ORAL ANDA 20 sections
tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 10544-587 TABLET 2 mg ORAL ANDA 18 sections
tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 10544-863 TABLET 2 mg ORAL ANDA 18 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 10544-890 TABLET 4 mg ORAL ANDA 22 sections
TIZANIDINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-220 TABLET 2 mg ORAL ANDA 16 sections
TIZANIDINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-221 TABLET 4 mg ORAL ANDA 16 sections
ZANAFLEX HUMAN PRESCRIPTION DRUG LABEL 1 16590-756 CAPSULE 6 mg ORAL NDA 24 sections
ZANAFLEX HUMAN PRESCRIPTION DRUG LABEL 1 16590-871 CAPSULE 4 mg ORAL NDA 24 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 16714-171 TABLET 2 mg ORAL ANDA 27 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 16714-172 TABLET 4 mg ORAL ANDA 27 sections
TIZANIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 21695-126 TABLET 2 mg ORAL ANDA 24 sections
TIZANIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 21695-127 TABLET 4 mg ORAL ANDA 24 sections
Zanaflex HUMAN PRESCRIPTION DRUG LABEL 1 21695-373 CAPSULE, GELATIN COATED 4 mg ORAL NDA 26 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 29300-168 TABLET 2 mg ORAL ANDA 26 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 29300-169 TABLET 4 mg ORAL ANDA 26 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 33261-103 TABLET 2 mg ORAL ANDA 22 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 33261-104 TABLET 4 mg ORAL ANDA 22 sections
Tizanidine HUMAN PRESCRIPTION DRUG LABEL 1 35356-662 TABLET 2 mg ORAL ANDA 27 sections